{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,22]],"date-time":"2026-10-22T07:21:03Z","timestamp":1792653663123,"version":"4.5.0"},"reference-count":186,"publisher":"Elsevier BV","issue":"7","license":[{"start":{"date-parts":[[2020,5,1]],"date-time":"2020-05-01T00:00:00Z","timestamp":1588291200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2020,5,1]],"date-time":"2020-05-01T00:00:00Z","timestamp":1588291200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"funder":[{"DOI":"10.13039\/100005204","name":"Siemens Foundation","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100005204","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100005616","name":"Allergan Foundation","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100005616","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100005564","name":"Gilead Sciences","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100005564","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100002491","name":"Bristol-Myers Squibb","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100002491","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100008953","name":"Prometheus","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100008953","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","gastrojournal.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Gastroenterology"],"published-print":{"date-parts":[[2020,5]]},"DOI":"10.1053\/j.gastro.2020.01.051","type":"journal-article","created":{"date-parts":[[2020,2,12]],"date-time":"2020-02-12T20:05:57Z","timestamp":1581537957000},"page":"1984-1998.e3","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":176,"title":["Therapeutic Landscape for NAFLD in 2020"],"prefix":"10.1053","volume":"158","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-8520-7398","authenticated-orcid":false,"given":"Brent A.","family":"Neuschwander-Tetri","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1053\/j.gastro.2020.01.051_bib1","doi-asserted-by":"crossref","first-page":"451","DOI":"10.1146\/annurev-pathol-012615-044224","article-title":"Nonalcoholic fatty liver disease: Pathogenesis and disease spectrum","volume":"11","author":"Hardy","year":"2016","journal-title":"Annu Rev Pathol"},{"key":"10.1053\/j.gastro.2020.01.051_bib2","doi-asserted-by":"crossref","first-page":"249","DOI":"10.1038\/nrd.2015.3","article-title":"Non-alcoholic steatohepatitis: emerging molecular targets and therapeutic strategies","volume":"15","author":"Musso","year":"2016","journal-title":"Nat Rev Drug Discov"},{"key":"10.1053\/j.gastro.2020.01.051_bib3","doi-asserted-by":"crossref","first-page":"247","DOI":"10.1016\/j.jcmgh.2019.04.007","article-title":"Metabolic targets in nonalcoholic fatty liver disease","volume":"8","author":"Esler","year":"2019","journal-title":"Cell Mol Gastroenterol Hepatol"},{"key":"10.1053\/j.gastro.2020.01.051_bib4","doi-asserted-by":"crossref","first-page":"1343","DOI":"10.1172\/JCI23621","article-title":"Sources of fatty acids stored in liver and secreted via lipoproteins in patients with nonalcoholic fatty liver disease","volume":"115","author":"Donnelly","year":"2005","journal-title":"J\u00a0Clin Invest"},{"key":"10.1053\/j.gastro.2020.01.051_bib5","doi-asserted-by":"crossref","first-page":"774","DOI":"10.1002\/hep.23719","article-title":"Hepatic lipotoxicity and the pathogenesis of nonalcoholic steatohepatitis: the central role of nontriglyceride fatty acid metabolites","volume":"52","author":"Neuschwander-Tetri","year":"2010","journal-title":"Hepatology"},{"key":"10.1053\/j.gastro.2020.01.051_bib6","doi-asserted-by":"crossref","first-page":"711","DOI":"10.1053\/j.gastro.2012.02.003","article-title":"Role of obesity and lipotoxicity in the development of nonalcoholic steatohepatitis: pathophysiology and clinical implications","volume":"142","author":"Cusi","year":"2012","journal-title":"Gastroenterology"},{"key":"10.1053\/j.gastro.2020.01.051_bib7","doi-asserted-by":"crossref","first-page":"291","DOI":"10.1016\/j.jhep.2011.05.019","article-title":"Lipotoxicity in NASH","volume":"56","author":"Fuchs","year":"2012","journal-title":"J\u00a0Hepatol"},{"key":"10.1053\/j.gastro.2020.01.051_bib8","doi-asserted-by":"crossref","first-page":"1049","DOI":"10.1016\/j.metabol.2016.02.014","article-title":"Molecular mechanisms of lipotoxicity and glucotoxicity in nonalcoholic fatty liver disease","volume":"65","author":"Mota","year":"2016","journal-title":"Metabolism"},{"key":"10.1053\/j.gastro.2020.01.051_bib9","doi-asserted-by":"crossref","first-page":"1769","DOI":"10.1053\/j.gastro.2016.02.066","article-title":"Pathogenesis of nonalcoholic steatohepatitis","volume":"150","author":"Machado","year":"2016","journal-title":"Gastroenterology"},{"key":"10.1053\/j.gastro.2020.01.051_bib10","doi-asserted-by":"crossref","first-page":"1758","DOI":"10.1194\/jlr.R066357","article-title":"Lipotoxic lethal and sublethal stress signaling in hepatocytes: relevance to NASH pathogenesis","volume":"57","author":"Hirsova","year":"2016","journal-title":"J\u00a0Lipid Res"},{"key":"10.1053\/j.gastro.2020.01.051_bib11","doi-asserted-by":"crossref","first-page":"280","DOI":"10.1016\/j.jhep.2017.11.014","article-title":"Lipotoxicity and the gut-liver axis in NASH pathogenesis","volume":"68","author":"Marra","year":"2018","journal-title":"J\u00a0Hepatol"},{"key":"10.1053\/j.gastro.2020.01.051_bib12","doi-asserted-by":"crossref","first-page":"282","DOI":"10.1053\/j.gastro.2018.06.031","article-title":"Bioactive lipid species and metabolic pathways in progression and resolution of nonalcoholic steatohepatitis","volume":"155","author":"Musso","year":"2018","journal-title":"Gastroenterology"},{"key":"10.1053\/j.gastro.2020.01.051_bib13","doi-asserted-by":"crossref","first-page":"10878","DOI":"10.1073\/pnas.91.23.10878","article-title":"\u03b2-Cell lipotoxicity in the pathogenesis of non-insulin-dependent diabetes mellitus of obese rats: Impairment in adipocyte-\u03b2-cell relationships","volume":"91","author":"Lee","year":"1994","journal-title":"Proc Natl Acad Sci USA"},{"key":"10.1053\/j.gastro.2020.01.051_bib14","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1016\/j.cmet.2009.03.011","article-title":"As a matter of fat","volume":"10","author":"Brookheart","year":"2009","journal-title":"Cell Metab"},{"key":"10.1053\/j.gastro.2020.01.051_bib15","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1186\/s12916-017-0806-8","article-title":"Non-alcoholic fatty liver disease","volume":"15","author":"Neuschwander-Tetri","year":"2017","journal-title":"BMC Med"},{"key":"10.1053\/j.gastro.2020.01.051_bib16","doi-asserted-by":"crossref","first-page":"1365","DOI":"10.1007\/s10620-016-4153-y","article-title":"Lifestyle and dietary interventions in the management of nonalcoholic fatty liver disease","volume":"61","author":"Hannah","year":"2016","journal-title":"Dig Dis Sci"},{"key":"10.1053\/j.gastro.2020.01.051_bib17","doi-asserted-by":"crossref","first-page":"1375","DOI":"10.1007\/s10620-016-4126-1","article-title":"Lifestyle interventions including nutrition, exercise, and supplements for nonalcoholic fatty liver disease in children","volume":"61","author":"Africa","year":"2016","journal-title":"Dig Dis Sci"},{"key":"10.1053\/j.gastro.2020.01.051_bib18","doi-asserted-by":"crossref","first-page":"392","DOI":"10.1177\/1756283X16638830","article-title":"Lifestyle changes for the treatment of nonalcoholic fatty liver disease: a review of observational studies and intervention trials","volume":"9","author":"Zelber-Sagi","year":"2016","journal-title":"Therap Adv Gastroenterol"},{"key":"10.1053\/j.gastro.2020.01.051_bib19","doi-asserted-by":"crossref","DOI":"10.1136\/bmjgast-2017-000139","article-title":"Efficacy of dietary and physical activity intervention in non-alcoholic fatty liver disease: a systematic review","volume":"4","author":"Kenneally","year":"2017","journal-title":"BMJ Open Gastroenterology"},{"key":"10.1053\/j.gastro.2020.01.051_bib20","doi-asserted-by":"crossref","first-page":"746","DOI":"10.1002\/hep.22009","article-title":"Behavior therapy for nonalcoholic fatty liver disease: the need for a multidisciplinary approach","volume":"47","author":"Bellentani","year":"2008","journal-title":"Hepatology"},{"key":"10.1053\/j.gastro.2020.01.051_bib21","doi-asserted-by":"crossref","first-page":"267","DOI":"10.1159\/000282101","article-title":"The effect of lifestyle changes in non-alcoholic fatty liver disease","volume":"28","author":"Centis","year":"2010","journal-title":"Dig Dis"},{"key":"10.1053\/j.gastro.2020.01.051_bib22","doi-asserted-by":"crossref","first-page":"k2538","DOI":"10.1136\/bmj.k2538","article-title":"Making progress on the global crisis of obesity and weight management","volume":"361","author":"Lean","year":"2018","journal-title":"BMJ"},{"key":"10.1053\/j.gastro.2020.01.051_bib23","doi-asserted-by":"crossref","first-page":"362","DOI":"10.1016\/j.jhep.2017.10.015","article-title":"Pharmacotherapy for NASH: current and emerging","volume":"68","author":"Konerman","year":"2018","journal-title":"J\u00a0Hepatol"},{"key":"10.1053\/j.gastro.2020.01.051_bib24","doi-asserted-by":"crossref","first-page":"k2426","DOI":"10.1136\/bmj.k2426","article-title":"Role of government policy in nutrition\u2014barriers to and opportunities for healthier eating","volume":"361","author":"Mozaffarian","year":"2018","journal-title":"BMJ"},{"key":"10.1053\/j.gastro.2020.01.051_bib25","doi-asserted-by":"crossref","first-page":"2613","DOI":"10.1161\/CIRCULATIONAHA.118.036751","article-title":"Cost-effectiveness of the US Food and Drug Administration added sugar labeling policy for improving diet and health","volume":"139","author":"Huang","year":"2019","journal-title":"Circulation"},{"key":"10.1053\/j.gastro.2020.01.051_bib26","first-page":"1065","article-title":"Global improvement in dietary quality could lead to substantial reduction in premature death","volume":"149","author":"Wang","year":"2019","journal-title":"J\u00a0Nutr"},{"key":"10.1053\/j.gastro.2020.01.051_bib27","doi-asserted-by":"crossref","first-page":"699","DOI":"10.1016\/j.metabol.2016.02.002","article-title":"Central nervous system regulation of eating: Insights from human brain imaging","volume":"65","author":"Farr","year":"2016","journal-title":"Metabolism"},{"key":"10.1053\/j.gastro.2020.01.051_bib28","doi-asserted-by":"crossref","first-page":"282","DOI":"10.1038\/nrn.2016.24","article-title":"Neurotrophic factor control of satiety and body weight","volume":"17","author":"Xu","year":"2016","journal-title":"Nat Rev Neurosci"},{"key":"10.1053\/j.gastro.2020.01.051_bib29","doi-asserted-by":"crossref","first-page":"758","DOI":"10.1016\/j.cell.2017.01.025","article-title":"Gut-brain cross-talk in metabolic control","volume":"168","author":"Clemmensen","year":"2017","journal-title":"Cell"},{"key":"10.1053\/j.gastro.2020.01.051_bib30","doi-asserted-by":"crossref","first-page":"59","DOI":"10.1111\/nyas.14179","article-title":"Neuropeptides at the crossroad of fear and hunger: a special focus on neuropeptide Y","volume":"1455","author":"Comeras","year":"2019","journal-title":"Ann N Y Acad Sci"},{"key":"10.1053\/j.gastro.2020.01.051_bib31","author":"Harvard"},{"key":"10.1053\/j.gastro.2020.01.051_bib32","doi-asserted-by":"crossref","first-page":"60","DOI":"10.1016\/j.metabol.2014.10.012","article-title":"Leptin in nonalcoholic fatty liver disease: a narrative review","volume":"64","author":"Polyzos","year":"2015","journal-title":"Metabolism"},{"key":"10.1053\/j.gastro.2020.01.051_bib33","doi-asserted-by":"crossref","first-page":"309","DOI":"10.1677\/JOE-08-0087","article-title":"Antagonism of central melanin-concentrating hormone 1 receptor alleviates steatohepatitis in mice","volume":"198","author":"Ito","year":"2008","journal-title":"J\u00a0Endocrinol"},{"key":"10.1053\/j.gastro.2020.01.051_bib34","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1016\/j.ejphar.2016.12.018","article-title":"A\u00a0novel and selective melanin-concentrating hormone receptor 1 antagonist ameliorates obesity and hepatic steatosis in diet-induced obese rodent models","volume":"796","author":"Kawata","year":"2017","journal-title":"Eur J Pharmacol"},{"key":"10.1053\/j.gastro.2020.01.051_bib35","doi-asserted-by":"crossref","first-page":"344","DOI":"10.1016\/j.cmet.2015.12.008","article-title":"FGF21 regulates sweet and alcohol preference","volume":"23","author":"Talukdar","year":"2016","journal-title":"Cell Metab"},{"key":"10.1053\/j.gastro.2020.01.051_bib36","doi-asserted-by":"crossref","first-page":"246","DOI":"10.1016\/j.cmet.2019.01.004","article-title":"A\u00a0dozen years of discovery: Insights into the physiology and pharmacology of FGF21","volume":"29","author":"Kliewer","year":"2019","journal-title":"Cell Metab"},{"key":"10.1053\/j.gastro.2020.01.051_bib37","doi-asserted-by":"crossref","first-page":"379","DOI":"10.1053\/j.gastro.2015.04.014","article-title":"Bariatric surgery reduces features of nonalcoholic steatohepatitis in morbidly obese patients","volume":"149","author":"Lassailly","year":"2015","journal-title":"Gastroenterology"},{"key":"10.1053\/j.gastro.2020.01.051_bib38","doi-asserted-by":"crossref","first-page":"1909","DOI":"10.1126\/science.1109951","article-title":"The gut and energy balance: visceral allies in the obesity wars","volume":"307","author":"Badman","year":"2005","journal-title":"Science"},{"key":"10.1053\/j.gastro.2020.01.051_bib39","doi-asserted-by":"crossref","first-page":"262","DOI":"10.1007\/s13679-015-0158-7","article-title":"What is the mechanism behind weight loss maintenance with gastric bypass?","volume":"4","author":"Chakravartty","year":"2015","journal-title":"Curr Obes Rep"},{"key":"10.1053\/j.gastro.2020.01.051_bib40","doi-asserted-by":"crossref","first-page":"411","DOI":"10.1152\/physrev.00031.2014","article-title":"Ghrelin, CCK, GLP-1, and PYY(3\u201336): secretory controls and physiological roles in eating and glycemia in health, obesity, and after RYGB","volume":"97","author":"Steinert","year":"2017","journal-title":"Physiol Rev"},{"key":"10.1053\/j.gastro.2020.01.051_bib41","doi-asserted-by":"crossref","first-page":"42","DOI":"10.5946\/ce.2017.013","article-title":"Recent clinical results of endoscopic bariatric therapies as an obesity intervention","volume":"50","author":"Bazerbachi","year":"2017","journal-title":"Clin Endosc"},{"key":"10.1053\/j.gastro.2020.01.051_bib42","doi-asserted-by":"crossref","first-page":"205","DOI":"10.1002\/oby.22347","article-title":"A\u00a0randomized, double-blind, placebo-controlled study of gelesis100: a novel nonsystemic oral hydrogel for weight loss","volume":"27","author":"Greenway","year":"2019","journal-title":"Obesity (Silver Spring)"},{"key":"10.1053\/j.gastro.2020.01.051_bib43","doi-asserted-by":"crossref","first-page":"926","DOI":"10.1111\/j.1572-0241.2003.07375.x","article-title":"Orlistat in the treatment of NASH: a case series","volume":"98","author":"Harrison","year":"2003","journal-title":"Am J Gastroenterol"},{"key":"10.1053\/j.gastro.2020.01.051_bib44","doi-asserted-by":"crossref","first-page":"639","DOI":"10.1016\/j.cgh.2006.02.004","article-title":"A\u00a0double-blind randomized placebo-controlled trial of orlistat for the treatment of nonalcoholic fatty liver disease","volume":"4","author":"Zelber-Sagi","year":"2006","journal-title":"Clin Gastroenterol Hepatol"},{"key":"10.1053\/j.gastro.2020.01.051_bib45","doi-asserted-by":"crossref","first-page":"2512","DOI":"10.1007\/s10620-006-9631-1","article-title":"Orlistat reverse fatty infiltration and improves hepatic fibrosis in obese patients with nonalcoholic steatohepatitis (NASH)","volume":"52","author":"Hussein","year":"2007","journal-title":"Dig Dis Sci"},{"key":"10.1053\/j.gastro.2020.01.051_bib46","doi-asserted-by":"crossref","first-page":"665","DOI":"10.1038\/nrg3941","article-title":"Exploring the emerging complexity in transcriptional regulation of energy homeostasis","volume":"16","author":"Lempradl","year":"2015","journal-title":"Nat Rev Genetics"},{"key":"10.1053\/j.gastro.2020.01.051_bib47","doi-asserted-by":"crossref","first-page":"691","DOI":"10.1002\/oby.22456","article-title":"Metabolic determinants of weight gain in humans","volume":"27","author":"Piaggi","year":"2019","journal-title":"Obesity (Silver Spring)"},{"key":"10.1053\/j.gastro.2020.01.051_bib48","doi-asserted-by":"crossref","first-page":"12","DOI":"10.1002\/hep.21821","article-title":"Food energy efficiency, cannabinoids, and a slow death of the weight loss dogma","volume":"46","author":"Neuschwander-Tetri","year":"2007","journal-title":"Hepatology"},{"key":"10.1053\/j.gastro.2020.01.051_bib49","doi-asserted-by":"crossref","first-page":"65","DOI":"10.1146\/annurev-pharmtox-010716-104727","article-title":"Emerging pharmacological targets for the treatment of nonalcoholic fatty liver disease, insulin resistance, and type 2 diabetes","volume":"59","author":"Goedeke","year":"2019","journal-title":"Annu Rev Pharmacol Toxicol"},{"key":"10.1053\/j.gastro.2020.01.051_bib50","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1016\/j.cmet.2018.11.002","article-title":"New advances in adaptive thermogenesis: UCP1 and beyond","volume":"29","author":"Chouchani","year":"2019","journal-title":"Cell Metab"},{"key":"10.1053\/j.gastro.2020.01.051_bib51","doi-asserted-by":"crossref","first-page":"739","DOI":"10.1016\/j.cmet.2015.04.004","article-title":"Adaptation of hepatic mitochondrial function in humans with non-alcoholic fatty liver is lost in steatohepatitis","volume":"21","author":"Koliaki","year":"2015","journal-title":"Cell Metab"},{"key":"10.1053\/j.gastro.2020.01.051_bib52","doi-asserted-by":"crossref","first-page":"68","DOI":"10.1002\/hep.22940","article-title":"Independent effects of physical activity in patients with nonalcoholic fatty liver disease","volume":"50","author":"St George","year":"2009","journal-title":"Hepatology"},{"key":"10.1053\/j.gastro.2020.01.051_bib53","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0046819","article-title":"Regular exercise is associated with a reduction in the risk of NAFLD and decreased liver enzymes in individuals with NAFLD independent of obesity in Korean adults","volume":"7","author":"Bae","year":"2012","journal-title":"PLoS One"},{"key":"10.1053\/j.gastro.2020.01.051_bib54","doi-asserted-by":"crossref","first-page":"791","DOI":"10.1016\/j.jhep.2016.05.026","article-title":"Effect of exercise on the development of new fatty liver and the resolution of existing fatty liver","volume":"65","author":"Sung","year":"2016","journal-title":"J\u00a0Hepatol"},{"key":"10.1053\/j.gastro.2020.01.051_bib55","doi-asserted-by":"crossref","first-page":"1026","DOI":"10.1002\/hep.28132","article-title":"Physical activity and liver diseases","volume":"63","author":"Berzigotti","year":"2016","journal-title":"Hepatology"},{"key":"10.1053\/j.gastro.2020.01.051_bib56","doi-asserted-by":"crossref","first-page":"829","DOI":"10.1016\/j.jhep.2017.05.016","article-title":"Treatment of NAFLD with diet, physical activity and exercise","volume":"67","author":"Romero-G\u00f3mez","year":"2017","journal-title":"J\u00a0Hepatol"},{"key":"10.1053\/j.gastro.2020.01.051_bib57","doi-asserted-by":"crossref","first-page":"478","DOI":"10.1172\/JCI78362","article-title":"Brown and beige fat in humans: thermogenic adipocytes that control energy and glucose homeostasis","volume":"125","author":"Sidossis","year":"2015","journal-title":"J\u00a0Clin Invest"},{"key":"10.1053\/j.gastro.2020.01.051_bib58","doi-asserted-by":"crossref","first-page":"232","DOI":"10.1016\/j.pcad.2018.07.002","article-title":"Role of human brown fat in obesity, metabolism and cardiovascular disease: strategies to turn up the heat","volume":"61","author":"Ruiz","year":"2018","journal-title":"Prog Cardiovasc Dis"},{"key":"10.1053\/j.gastro.2020.01.051_bib59","doi-asserted-by":"crossref","first-page":"224","DOI":"10.1016\/S2213-8587(16)30155-3","article-title":"Clinical relevance of the bile acid receptor TGR5 in metabolism","volume":"5","author":"van Nierop","year":"2017","journal-title":"Lancet Diabetes Endocrinol"},{"key":"10.1053\/j.gastro.2020.01.051_bib60","doi-asserted-by":"crossref","first-page":"1513","DOI":"10.1172\/JCI64551","article-title":"The TGR5 receptor mediates bile acid\u2013induced itch and analgesia","volume":"123","author":"Alemi","year":"2013","journal-title":"J\u00a0Clin Invest"},{"key":"10.1053\/j.gastro.2020.01.051_bib61","doi-asserted-by":"crossref","first-page":"935","DOI":"10.1016\/j.cmet.2017.03.005","article-title":"FGF21 regulates metabolism through adipose-dependent and -independent mechanisms","volume":"25","author":"BonDurant","year":"2017","journal-title":"Cell Metab"},{"key":"10.1053\/j.gastro.2020.01.051_bib62","doi-asserted-by":"crossref","first-page":"3346","DOI":"10.2337\/db14-0302","article-title":"GLP-1 agonism stimulates brown adipose tissue thermogenesis and browning through hypothalamic AMPK","volume":"63","author":"Beiroa","year":"2014","journal-title":"Diabetes"},{"key":"10.1053\/j.gastro.2020.01.051_bib63","doi-asserted-by":"crossref","first-page":"213","DOI":"10.1016\/j.diabet.2019.01.008","article-title":"Beneficial effects of SGLT2 inhibitors on fatty liver in type 2 diabetes: a common comorbidity associated with severe complications","volume":"45","author":"Scheen","year":"2019","journal-title":"Diabetes Metab"},{"key":"10.1053\/j.gastro.2020.01.051_bib64","doi-asserted-by":"crossref","first-page":"125","DOI":"10.1111\/dom.12578","article-title":"Energy balance and metabolic changes with sodium-glucose co-transporter 2 inhibition","volume":"18","author":"Rajeev","year":"2016","journal-title":"Diabetes Obes Metab"},{"key":"10.1053\/j.gastro.2020.01.051_bib65","doi-asserted-by":"crossref","first-page":"1801","DOI":"10.2337\/dc18-0165","article-title":"Effect of empagliflozin on liver fat in patients with type 2 diabetes and nonalcoholic fatty liver disease: A randomized controlled trial (E-LIFT trial)","volume":"41","author":"Kuchay","year":"2018","journal-title":"Diabetes Care"},{"key":"10.1053\/j.gastro.2020.01.051_bib66","doi-asserted-by":"crossref","first-page":"1109","DOI":"10.1517\/14728222.2016.1168808","article-title":"Sodium glucose cotransporter SGLT1 as a therapeutic target in diabetes mellitus","volume":"20","author":"Song","year":"2016","journal-title":"Expert Opin Ther Targets"},{"key":"10.1053\/j.gastro.2020.01.051_bib67","doi-asserted-by":"crossref","first-page":"359","DOI":"10.1016\/j.molmed.2016.03.005","article-title":"Reappraisal of GIP pharmacology for metabolic diseases","volume":"22","author":"Finan","year":"2016","journal-title":"Trends Mol Med"},{"key":"10.1053\/j.gastro.2020.01.051_bib68","doi-asserted-by":"crossref","first-page":"167","DOI":"10.1016\/j.cmet.2009.08.001","article-title":"TGR5-mediated bile acid sensing controls glucose homeostasis","volume":"10","author":"Thomas","year":"2009","journal-title":"Cell Metab"},{"key":"10.1053\/j.gastro.2020.01.051_bib69","doi-asserted-by":"crossref","first-page":"1584","DOI":"10.1002\/hep.23569","article-title":"Glucagon-like peptide-1 receptor is present on human hepatocytes and has a direct role in decreasing hepatic steatosis in\u00a0vitro by modulating elements of the insulin signaling pathway","volume":"51","author":"Gupta","year":"2010","journal-title":"Hepatology"},{"key":"10.1053\/j.gastro.2020.01.051_bib70","doi-asserted-by":"crossref","first-page":"2318","DOI":"10.1002\/hep.30670","article-title":"Incretin-based therapies for the management of nonalcoholic fatty liver disease in patients with type 2 diabetes","volume":"69","author":"Cusi","year":"2019","journal-title":"Hepatology"},{"key":"10.1053\/j.gastro.2020.01.051_bib71","doi-asserted-by":"crossref","first-page":"679","DOI":"10.1016\/S0140-6736(15)00803-X","article-title":"Liraglutide safety and efficacy in patients with non-alcoholic steatohepatitis (LEAN): a multicentre, double-blind, randomised, placebo-controlled phase 2 study","volume":"387","author":"Armstrong","year":"2016","journal-title":"Lancet"},{"key":"10.1053\/j.gastro.2020.01.051_bib72","doi-asserted-by":"crossref","first-page":"42","DOI":"10.1016\/j.mce.2015.07.003","article-title":"Emerging opportunities for the treatment of metabolic diseases: glucagon-like peptide-1 based multi-agonists","volume":"418","author":"Finan","year":"2015","journal-title":"Mol Cell Endocrinol"},{"key":"10.1053\/j.gastro.2020.01.051_bib73","doi-asserted-by":"crossref","first-page":"51","DOI":"10.1016\/j.cmet.2016.06.021","article-title":"Unimolecular polypharmacy for treatment of diabetes and obesity","volume":"24","author":"Tsch\u00f6p","year":"2016","journal-title":"Cell Metab"},{"key":"10.1053\/j.gastro.2020.01.051_bib74","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1021\/acsptsci.8b00009","article-title":"Beyond glucagon-like peptide-1: Is G-protein coupled receptor polypharmacology the path forward to treating metabolic diseases?","volume":"1","author":"Sloop","year":"2018","journal-title":"ACS Pharmacol Transl Sci"},{"key":"10.1053\/j.gastro.2020.01.051_bib75","doi-asserted-by":"crossref","DOI":"10.2337\/db19-134-OR","article-title":"134-OR: Effects of tirzepatide (TZP), a novel dual GIP and GLP-1 receptor agonist, on biomarkers of nonalcoholic steatohepatitis (NASH) in patients with T2D","volume":"68","author":"Hartman","year":"2019","journal-title":"Diabetes"},{"key":"10.1053\/j.gastro.2020.01.051_bib76","doi-asserted-by":"crossref","first-page":"173","DOI":"10.1146\/annurev-nutr-071816-064800","article-title":"Fibroblast growth factor 21: a versatile regulator of metabolic homeostasis","volume":"38","author":"BonDurant","year":"2018","journal-title":"Annu Rev Nutr"},{"key":"10.1053\/j.gastro.2020.01.051_bib77","doi-asserted-by":"crossref","first-page":"960","DOI":"10.1210\/er.2018-00134","article-title":"Fibroblast growth factor 15\/19: from basic functions to therapeutic perspectives","volume":"39","author":"Somm","year":"2018","journal-title":"Endocr Rev"},{"key":"10.1053\/j.gastro.2020.01.051_bib78","doi-asserted-by":"crossref","first-page":"25123","DOI":"10.1074\/jbc.M112.375907","article-title":"Activation of the farnesoid X receptor induces hepatic expression and secretion of fibroblast growth factor 21","volume":"287","author":"Cyphert","year":"2012","journal-title":"J\u00a0Biol Chem"},{"key":"10.1053\/j.gastro.2020.01.051_bib79","doi-asserted-by":"crossref","first-page":"3093","DOI":"10.1007\/s00125-011-2317-z","article-title":"Exenatide decreases hepatic fibroblast growth factor 21 resistance in non-alcoholic fatty liver disease in a mouse model of obesity and in a randomised controlled trial","volume":"54","author":"Samson","year":"2011","journal-title":"Diabetologia"},{"key":"10.1053\/j.gastro.2020.01.051_bib80","doi-asserted-by":"crossref","first-page":"10023","DOI":"10.1074\/jbc.M808818200","article-title":"Fibroblast growth factor-19, a novel factor that inhibits hepatic fatty acid synthesis","volume":"284","author":"Bhatnagar","year":"2009","journal-title":"J\u00a0Biol Chem"},{"key":"10.1053\/j.gastro.2020.01.051_bib81","doi-asserted-by":"crossref","first-page":"3306","DOI":"10.1158\/0008-5472.CAN-14-0208","article-title":"Separating tumorigenicity from bile acid regulatory activity for endocrine hormone FGF19","volume":"74","author":"Zhou","year":"2014","journal-title":"Cancer Res"},{"key":"10.1053\/j.gastro.2020.01.051_bib82","doi-asserted-by":"crossref","first-page":"1182","DOI":"10.1016\/j.jhep.2017.01.027","article-title":"Mouse species-specific control of hepatocarcinogenesis and metabolism by FGF19\/FGF15","volume":"66","author":"Zhou","year":"2017","journal-title":"J\u00a0Hepatol"},{"key":"10.1053\/j.gastro.2020.01.051_bib83","doi-asserted-by":"crossref","first-page":"1174","DOI":"10.1016\/S0140-6736(18)30474-4","article-title":"NGM282 for treatment of non-alcoholic steatohepatitis: a multicentre, randomised, double-blind, placebo-controlled, phase 2 trial","volume":"391","author":"Harrison","year":"2018","journal-title":"Lancet"},{"key":"10.1053\/j.gastro.2020.01.051_bib84","author":"Harrison"},{"key":"10.1053\/j.gastro.2020.01.051_bib85","doi-asserted-by":"crossref","first-page":"735","DOI":"10.1016\/j.jhep.2018.11.032","article-title":"Rosuvastatin improves the FGF19 analogue NGM282-associated lipid changes in patients with non-alcoholic steatohepatitis","volume":"70","author":"Rinella","year":"2019","journal-title":"J\u00a0Hepatol"},{"key":"10.1053\/j.gastro.2020.01.051_bib86","doi-asserted-by":"crossref","first-page":"74","DOI":"10.1038\/nrendo.2016.206","article-title":"FGF21 and metabolic disease in 2016: a new frontier in FGF21 biology","volume":"13","author":"Potthoff","year":"2017","journal-title":"Nat Rev Endocrinol"},{"key":"10.1053\/j.gastro.2020.01.051_bib87","doi-asserted-by":"crossref","first-page":"223","DOI":"10.1146\/annurev-physiol-021115-105339","article-title":"Understanding the physiology of FGF21","volume":"78","author":"Fisher","year":"2016","journal-title":"Annu Rev Physiol"},{"key":"10.1053\/j.gastro.2020.01.051_bib88","doi-asserted-by":"crossref","first-page":"4057","DOI":"10.2337\/db14-0595","article-title":"Circulating FGF21 is liver derived and enhances glucose uptake during refeeding and overfeeding","volume":"63","author":"Markan","year":"2014","journal-title":"Diabetes"},{"key":"10.1053\/j.gastro.2020.01.051_bib89","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1016\/j.celrep.2016.08.086","article-title":"mTORC1 is a major regulatory node in the FGF21 signaling network in adipocytes","volume":"17","author":"Minard Annabel","year":"2016","journal-title":"Cell Rep"},{"key":"10.1053\/j.gastro.2020.01.051_bib90","doi-asserted-by":"crossref","first-page":"29751","DOI":"10.1074\/jbc.M114.565960","article-title":"Fibroblast growth factor 21 is regulated by the IRE1a-XBP1 branch of the unfolded protein response and counteracts endoplasmic reticulum stress-induced hepatic steatosis","volume":"289","author":"Jiang","year":"2014","journal-title":"J\u00a0Biol Chem"},{"key":"10.1053\/j.gastro.2020.01.051_bib91","doi-asserted-by":"crossref","first-page":"472","DOI":"10.3389\/fgene.2019.00472","article-title":"Carbohydrate sensing through the transcription factor ChREBP","volume":"10","author":"Ortega-Prieto","year":"2019","journal-title":"Front Genet"},{"key":"10.1053\/j.gastro.2020.01.051_bib92","doi-asserted-by":"crossref","first-page":"1395","DOI":"10.1016\/j.molmet.2017.08.004","article-title":"Fibroblast growth factor 21 (FGF21) is robustly induced by ethanol and has a protective role in ethanol associated liver injury","volume":"6","author":"Desai","year":"2017","journal-title":"Mol Metab"},{"key":"10.1053\/j.gastro.2020.01.051_bib93","doi-asserted-by":"crossref","first-page":"96","DOI":"10.1016\/j.molmet.2018.03.010","article-title":"FGF21, a liver hormone that inhibits alcohol intake in mice, increases in human circulation after acute alcohol ingestion and sustained binge drinking at Oktoberfest","volume":"11","author":"S\u00f8berg","year":"2018","journal-title":"Mol Metab"},{"key":"10.1053\/j.gastro.2020.01.051_bib94","doi-asserted-by":"crossref","first-page":"200","DOI":"10.1038\/nm.2297","article-title":"Brown adipose tissue activity controls triglyceride clearance","volume":"17","author":"Bartelt","year":"2011","journal-title":"Nat Med"},{"key":"10.1053\/j.gastro.2020.01.051_bib95","doi-asserted-by":"crossref","first-page":"56","DOI":"10.1016\/j.molmet.2018.03.002","article-title":"Deficiency of fibroblast growth factor 21 (FGF21) promotes hepatocellular carcinoma (HCC) in mice on a long term obesogenic diet","volume":"13","author":"Singhal","year":"2018","journal-title":"Mol Metab"},{"key":"10.1053\/j.gastro.2020.01.051_bib96","doi-asserted-by":"crossref","first-page":"e8791","DOI":"10.15252\/emmm.201708791","article-title":"FGF21 gene therapy as treatment for obesity and insulin resistance","volume":"10","author":"Jimenez","year":"2018","journal-title":"EMBO Mol Med"},{"key":"10.1053\/j.gastro.2020.01.051_bib97","doi-asserted-by":"crossref","first-page":"468","DOI":"10.1210\/er.2017-00016","article-title":"Fibroblast growth factor 21-metabolic role in mice and men","volume":"38","author":"Staiger","year":"2017","journal-title":"Endocr Rev"},{"key":"10.1053\/j.gastro.2020.01.051_bib98","doi-asserted-by":"crossref","first-page":"382","DOI":"10.1097\/MEG.0b013e328345c8c7","article-title":"Elevated hepatic fatty acid oxidation, high plasma fibroblast growth factor 21, and fasting bile acids in nonalcoholic steatohepatitis","volume":"23","author":"Dasarathy","year":"2011","journal-title":"Eur J Gastroenterol Hepatol"},{"key":"10.1053\/j.gastro.2020.01.051_bib99","doi-asserted-by":"crossref","first-page":"1045","DOI":"10.1016\/j.cmet.2017.04.009","article-title":"FGF21 is a sugar-induced hormone associated with sweet intake and preference in humans","volume":"25","author":"S\u00f8berg","year":"2017","journal-title":"Cell Metab"},{"key":"10.1053\/j.gastro.2020.01.051_bib100","doi-asserted-by":"crossref","first-page":"427","DOI":"10.1016\/j.cmet.2016.02.001","article-title":"A\u00a0long-acting FGF21 molecule, PF-05231023, decreases body weight and improves lipid profile in non-human primates and type 2 diabetic subjects","volume":"23","author":"Talukdar","year":"2016","journal-title":"Cell Metab"},{"key":"10.1053\/j.gastro.2020.01.051_bib101","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1002\/oby.22344","article-title":"Pegbelfermin (BMS-986036), PEGylated FGF21, in patients with obesity and type 2 diabetes: results from a randomized phase 2 study","volume":"27","author":"Charles","year":"2019","journal-title":"Obesity (Silver Spring)"},{"key":"10.1053\/j.gastro.2020.01.051_bib102","doi-asserted-by":"crossref","first-page":"2705","DOI":"10.1016\/S0140-6736(18)31785-9","article-title":"Pegbelfermin (BMS-986036), a PEGylated fibroblast growth factor 21 analogue, in patients with non-alcoholic steatohepatitis: a randomised, double-blind, placebo-controlled, phase 2a trial","volume":"392","author":"Sanyal","year":"2019","journal-title":"Lancet"},{"key":"10.1053\/j.gastro.2020.01.051_bib103","first-page":"19","article-title":"FGF21-receptor agonists: an emerging therapeutic class for obesity-related diseases","volume":"30","author":"Sonoda","year":"2017","journal-title":"Horm Mol Biol Clin Investig"},{"key":"10.1053\/j.gastro.2020.01.051_bib104","doi-asserted-by":"crossref","first-page":"1753","DOI":"10.1042\/BST20180004","article-title":"Structure, activation and dysregulation of fibroblast growth factor receptor kinases: perspectives for clinical targeting","volume":"46","author":"Farrell","year":"2018","journal-title":"Biochem Soc Trans"},{"key":"10.1053\/j.gastro.2020.01.051_bib105","doi-asserted-by":"crossref","first-page":"43","DOI":"10.1055\/s-2001-12928","article-title":"Peroxisomal beta-oxidation and steatohepatitis","volume":"21","author":"Rao","year":"2001","journal-title":"Semin Liver Dis"},{"key":"10.1053\/j.gastro.2020.01.051_bib106","doi-asserted-by":"crossref","first-page":"345","DOI":"10.2169\/internalmedicine.41.345","article-title":"Tamoxifen-induced nonalcoholic steatohepatitis in breast cancer patients treated with adjuvent tamoxifen","volume":"41","author":"Nemoto","year":"2002","journal-title":"Intern Med"},{"key":"10.1053\/j.gastro.2020.01.051_bib107","doi-asserted-by":"crossref","first-page":"332","DOI":"10.2337\/db07-1318","article-title":"Activation of peroxisome proliferator-activated receptor (PPAR)d promotes reversal of multiple metabolic abnormalities, reduces oxidative stress, and increases fatty acid oxidation in moderately obese men","volume":"57","author":"Ris\u00e9rus","year":"2008","journal-title":"Diabetes"},{"key":"10.1053\/j.gastro.2020.01.051_bib108","doi-asserted-by":"crossref","first-page":"171","DOI":"10.1097\/MOL.0b013e32835cc949","article-title":"Peroxisome proliferator-activated receptor d: a multifaceted metabolic player","volume":"24","author":"Bojic","year":"2013","journal-title":"Curr Opin Lipidol"},{"key":"10.1053\/j.gastro.2020.01.051_bib109","doi-asserted-by":"crossref","first-page":"1827","DOI":"10.1210\/jc.2006-1785","article-title":"Genetic variations in PPARD and PPARGC1A determine mitochondrial function and change in aerobic physical fitness and insulin sensitivity during lifestyle intervention","volume":"92","author":"Stefan","year":"2007","journal-title":"J\u00a0Clin Endocrinol Metab"},{"key":"10.1053\/j.gastro.2020.01.051_bib110","doi-asserted-by":"crossref","first-page":"4920","DOI":"10.1210\/endo.139.12.6384","article-title":"Peroxisome proliferator-activated receptors g and a mediate in\u00a0vivo regulation of uncoupling protein (UCP-1, UCP-2, UCP-3) gene expression","volume":"139","author":"Kelly","year":"1998","journal-title":"Endocrinology"},{"key":"10.1053\/j.gastro.2020.01.051_bib111","doi-asserted-by":"crossref","first-page":"1675","DOI":"10.1056\/NEJMoa0907929","article-title":"Pioglitazone, vitamin E, or placebo for nonalcoholic steatohepatitis","volume":"362","author":"Sanyal","year":"2010","journal-title":"N\u00a0Engl J Med"},{"key":"10.1053\/j.gastro.2020.01.051_bib112","doi-asserted-by":"crossref","first-page":"558","DOI":"10.1016\/j.cgh.2017.12.001","article-title":"Response to pioglitazone in patients with nonalcoholic steatohepatitis with vs without type 2 diabetes","volume":"16","author":"Bril","year":"2018","journal-title":"Clin Gastroenterol Hepatol"},{"key":"10.1053\/j.gastro.2020.01.051_bib113","doi-asserted-by":"crossref","first-page":"1147","DOI":"10.1053\/j.gastro.2016.01.038","article-title":"Elafibranor, an agonist of the peroxisome proliferator-activated receptor-a and -d, induces resolution of nonalcoholic steatohepatitis without fibrosis worsening","volume":"150","author":"Ratziu","year":"2016","journal-title":"Gastroenterology"},{"key":"10.1053\/j.gastro.2020.01.051_bib114","doi-asserted-by":"crossref","first-page":"1173","DOI":"10.1089\/thy.2018.0664","article-title":"Nonalcoholic fatty liver disease and hypercholesterolemia: roles of thyroid hormones, metabolites, and agonists","volume":"29","author":"Sinha","year":"2019","journal-title":"Thyroid"},{"key":"10.1053\/j.gastro.2020.01.051_bib115","doi-asserted-by":"crossref","first-page":"373","DOI":"10.1016\/j.atherosclerosis.2013.07.056","article-title":"Lipid lowering in healthy volunteers treated with multiple doses of MGL-3196, a liver-targeted thyroid hormone receptor-beta agonist","volume":"230","author":"Taub","year":"2013","journal-title":"Atherosclerosis"},{"key":"10.1053\/j.gastro.2020.01.051_bib116","doi-asserted-by":"crossref","first-page":"2012","DOI":"10.1016\/S0140-6736(19)32517-6","article-title":"Resmetirom (MGL-3196) for the treatment of non-alcoholic steatohepatitis: a multicentre, randomised, double-blind, placebo-controlled, phase 2 trial","volume":"394","author":"Harrison","year":"2019","journal-title":"Lancet"},{"key":"10.1053\/j.gastro.2020.01.051_bib117","doi-asserted-by":"crossref","first-page":"1539","DOI":"10.1126\/science.1160794","article-title":"A\u00a0stress signaling pathway in adipose tissue regulates hepatic insulin resistance","volume":"322","author":"Sabio","year":"2008","journal-title":"Science"},{"key":"10.1053\/j.gastro.2020.01.051_bib118","doi-asserted-by":"crossref","first-page":"367","DOI":"10.1038\/nrm2391","article-title":"Adipocyte dysfunctions linking obesity to insulin resistance and type 2 diabetes","volume":"9","author":"Guilherme","year":"2008","journal-title":"Nat Rev Mol Cell Biol"},{"key":"10.1053\/j.gastro.2020.01.051_bib119","doi-asserted-by":"crossref","first-page":"3428","DOI":"10.1074\/jbc.M109.074252","article-title":"Adipocyte apoptosis, a link between obesity, insulin resistance, and hepatic steatosis","volume":"285","author":"Alkhouri","year":"2010","journal-title":"J\u00a0Biol Chem"},{"key":"10.1053\/j.gastro.2020.01.051_bib120","doi-asserted-by":"crossref","first-page":"1087","DOI":"10.1002\/hep.23116","article-title":"Importance of changes in adipose tissue insulin resistance to histological response during thiazolidinedione treatment of patients with nonalcoholic steatohepatitis","volume":"50","author":"Gastaldelli","year":"2009","journal-title":"Hepatology"},{"key":"10.1053\/j.gastro.2020.01.051_bib121","doi-asserted-by":"crossref","first-page":"e3645","DOI":"10.1136\/bmj.e3645","article-title":"The use of pioglitazone and the risk of bladder cancer in people with type 2 diabetes: nested case-control study","volume":"344","author":"Azoulay","year":"2012","journal-title":"BMJ"},{"key":"10.1053\/j.gastro.2020.01.051_bib122","doi-asserted-by":"crossref","first-page":"265","DOI":"10.1001\/jama.2015.7996","article-title":"Pioglitazone use and risk of bladder cancer and other common cancers in persons with diabetes","volume":"314","author":"Lewis","year":"2015","journal-title":"JAMA"},{"key":"10.1053\/j.gastro.2020.01.051_bib123","doi-asserted-by":"crossref","first-page":"573","DOI":"10.1016\/j.cmet.2014.08.005","article-title":"Thiazolidinediones and the promise of insulin sensitization in type 2 diabetes","volume":"20","author":"Soccio","year":"2014","journal-title":"Cell Metab"},{"key":"10.1053\/j.gastro.2020.01.051_bib124","doi-asserted-by":"crossref","first-page":"1394","DOI":"10.1136\/gut.2010.222844","article-title":"Hepatic fatty acid translocase CD36 upregulation is associated with insulin resistance, hyperinsulinaemia and increased steatosis in non-alcoholic steatohepatitis and chronic hepatitis C","volume":"60","author":"Miquilena-Colina","year":"2011","journal-title":"Gut"},{"key":"10.1053\/j.gastro.2020.01.051_bib125","doi-asserted-by":"crossref","first-page":"3159","DOI":"10.1096\/fj.14-249763","article-title":"Plasma membrane phospholipase A2 controls hepatocellular fatty acid uptake and is responsive to pharmacological modulation: implications for nonalcoholic steatohepatitis","volume":"28","author":"Stremmel","year":"2014","journal-title":"FASEB J"},{"key":"10.1053\/j.gastro.2020.01.051_bib126","doi-asserted-by":"crossref","first-page":"1116","DOI":"10.1258\/ebm.2011.011128","article-title":"The emerging roles of fatty acid translocase\/CD36 and the aryl hydrocarbon receptor in fatty liver disease","volume":"236","author":"He","year":"2011","journal-title":"Exp Biol Med (Maywood)"},{"key":"10.1053\/j.gastro.2020.01.051_bib127","doi-asserted-by":"crossref","first-page":"24644","DOI":"10.1074\/jbc.M109.034397","article-title":"Accelerated fatty acid oxidation in muscle averts fasting-induced hepatic steatosis in SJL\/J mice","volume":"284","author":"Guan","year":"2009","journal-title":"J\u00a0Biol Chem"},{"key":"10.1053\/j.gastro.2020.01.051_bib128","doi-asserted-by":"crossref","first-page":"4320","DOI":"10.1073\/pnas.1119908109","article-title":"Opposing effects of fructokinase C and A isoforms on fructose-induced metabolic syndrome in mice","volume":"109","author":"Ishimoto","year":"2012","journal-title":"Proc Natl Acad Sci U S A"},{"key":"10.1053\/j.gastro.2020.01.051_bib129","doi-asserted-by":"crossref","first-page":"159","DOI":"10.1146\/annurev.physiol.68.033104.152158","article-title":"LXRs and FXR: the yin and yang of cholesterol and fat metabolism","volume":"68","author":"Kalaany","year":"2006","journal-title":"Annu Rev Physiol"},{"key":"10.1053\/j.gastro.2020.01.051_bib130","doi-asserted-by":"crossref","first-page":"350","DOI":"10.1002\/hep.28709","article-title":"Bile acids and nonalcoholic fatty liver disease: Molecular insights and therapeutic perspectives","volume":"65","author":"Arab","year":"2017","journal-title":"Hepatology"},{"key":"10.1053\/j.gastro.2020.01.051_bib131","doi-asserted-by":"crossref","first-page":"2082","DOI":"10.1111\/liv.14209","article-title":"CONTROL: a randomized phase 2 study of obeticholic acid and atorvastatin on lipoproteins in nonalcoholic steatohepatitis patients","volume":"39","author":"Pockros","year":"2019","journal-title":"Liver Int"},{"key":"10.1053\/j.gastro.2020.01.051_bib132","doi-asserted-by":"crossref","first-page":"956","DOI":"10.1016\/S0140-6736(14)61933-4","article-title":"Farnesoid X nuclear receptor ligand obeticholic acid for non-cirrhotic, non-alcoholic steatohepatitis (FLINT): a multicentre, randomised, placebo-controlled trial","volume":"385","author":"Neuschwander-Tetri","year":"2015","journal-title":"Lancet"},{"issue":"Suppl 1","key":"10.1053\/j.gastro.2020.01.051_bib133","doi-asserted-by":"crossref","first-page":"e5","DOI":"10.1016\/S0618-8278(19)30006-4","article-title":"Positive results from REGENERATE: A phase 3 international, randomized, placebo-controlled study evaluating obeticholic acid treatment for NASH (abstract)","volume":"70","author":"Younossi","year":"2019","journal-title":"J\u00a0Hepatol"},{"key":"10.1053\/j.gastro.2020.01.051_bib134","doi-asserted-by":"crossref","first-page":"213","DOI":"10.1038\/nrm3312","article-title":"Transcriptional integration of metabolism by the nuclear sterol-activated receptors LXR and FXR","volume":"13","author":"Calkin","year":"2012","journal-title":"Nat Rev Mol Cell Biol"},{"key":"10.1053\/j.gastro.2020.01.051_bib135","doi-asserted-by":"crossref","first-page":"11245","DOI":"10.1073\/pnas.0404297101","article-title":"Central role for liver X receptor in insulin-mediated activation of Srebp-1c transcription and stimulation of fatty acid synthesis in liver","volume":"101","author":"Chen","year":"2004","journal-title":"Proc Natl Acad Sci U S A"},{"key":"10.1053\/j.gastro.2020.01.051_bib136","doi-asserted-by":"crossref","first-page":"556","DOI":"10.1053\/j.gastro.2007.11.037","article-title":"Hepatic fatty acid transporter Cd36 is a common target of LXR, PXR, and PPARg in promoting steatosis","volume":"134","author":"Zhou","year":"2008","journal-title":"Gastroenterology"},{"key":"10.1053\/j.gastro.2020.01.051_bib137","doi-asserted-by":"crossref","first-page":"7892","DOI":"10.1073\/pnas.1003585107","article-title":"A\u00a0feed-forward loop amplifies nutritional regulation of PNPLA3","volume":"107","author":"Huang","year":"2010","journal-title":"Proc Natl Acad Sci U S A"},{"key":"10.1053\/j.gastro.2020.01.051_bib138","doi-asserted-by":"crossref","first-page":"2427","DOI":"10.1002\/hep.30583","article-title":"PNPLA3, CGI-58, and inhibition of hepatic triglyceride hydrolysis in mice","volume":"69","author":"Wang","year":"2019","journal-title":"Hepatology"},{"key":"10.1053\/j.gastro.2020.01.051_bib139","doi-asserted-by":"crossref","first-page":"231","DOI":"10.1016\/j.cmet.2005.03.001","article-title":"LXRs regulate the balance between fat storage and oxidation","volume":"1","author":"Kalaany","year":"2005","journal-title":"Cell Metab"},{"key":"10.1053\/j.gastro.2020.01.051_bib140","doi-asserted-by":"crossref","first-page":"353","DOI":"10.1016\/j.molmet.2015.01.009","article-title":"The LXR inverse agonist SR9238 suppresses fibrosis in a model of non-alcoholic steatohepatitis","volume":"4","author":"Griffett","year":"2015","journal-title":"Mol Metab"},{"key":"10.1053\/j.gastro.2020.01.051_bib141","doi-asserted-by":"crossref","first-page":"443","DOI":"10.1042\/BJ20141171","article-title":"Mitochondrial pyruvate transport: a historical perspective and future research directions","volume":"466","author":"McCommis","year":"2015","journal-title":"Biochem J"},{"key":"10.1053\/j.gastro.2020.01.051_bib142","doi-asserted-by":"crossref","first-page":"631","DOI":"10.1080\/13543784.2018.1494153","article-title":"MSDC-0602K, a metabolic modulator directed at the core pathology of non-alcoholic steatohepatitis","volume":"27","author":"Colca","year":"2018","journal-title":"Expert Opin Investig Drugs"},{"key":"10.1053\/j.gastro.2020.01.051_bib143","doi-asserted-by":"crossref","first-page":"275","DOI":"10.1016\/j.jcmgh.2018.09.017","article-title":"Treating hepatic steatosis and fibrosis by modulating mitochondrial pyruvate metabolism","volume":"7","author":"McCommis","year":"2019","journal-title":"Cell Mol Gastroenterol Hepatol"},{"key":"10.1053\/j.gastro.2020.01.051_bib144","author":"Harrison"},{"key":"10.1053\/j.gastro.2020.01.051_bib145","doi-asserted-by":"crossref","first-page":"1166","DOI":"10.1002\/hep.22774","article-title":"Abrogation of hepatic ATP-citrate lyase protects against fatty liver and ameliorates hyperglycemia in leptin receptor-deficient mice","volume":"49","author":"Wang","year":"2009","journal-title":"Hepatology"},{"key":"10.1053\/j.gastro.2020.01.051_bib146","doi-asserted-by":"crossref","first-page":"1047","DOI":"10.1016\/j.molmed.2017.09.001","article-title":"Targeting ATP-citrate lyase in hyperlipidemia and metabolic disorders","volume":"23","author":"Pinkosky","year":"2017","journal-title":"Trends Mol Med"},{"issue":"Suppl","key":"10.1053\/j.gastro.2020.01.051_bib147","doi-asserted-by":"crossref","first-page":"S138","DOI":"10.1194\/jlr.R800079-JLR200","article-title":"Fatty acid metabolism: target for metabolic syndrome","volume":"50","author":"Wakil","year":"2009","journal-title":"J\u00a0Lipid Res"},{"key":"10.1053\/j.gastro.2020.01.051_bib148","doi-asserted-by":"crossref","first-page":"1463","DOI":"10.1053\/j.gastro.2018.07.027","article-title":"GS-0976 reduces hepatic steatosis and fibrosis markers in patients with nonalcoholic fatty liver disease","volume":"155","author":"Loomba","year":"2018","journal-title":"Gastroenterology"},{"key":"10.1053\/j.gastro.2020.01.051_bib149","doi-asserted-by":"crossref","first-page":"S582","DOI":"10.1016\/S0168-8278(18)31423-5","article-title":"Safety, tolerability, pharmacokinetics and pharmacodynamics of a liver-targeting ACC inhibitor (PF-05221304) following single and multiple oral doses (abstract)","volume":"68","author":"Bergman","year":"2018","journal-title":"J\u00a0Hepatol"},{"key":"10.1053\/j.gastro.2020.01.051_bib150","doi-asserted-by":"crossref","first-page":"394","DOI":"10.1016\/j.cmet.2017.07.009","article-title":"Acetyl CoA carboxylase inhibition reduces hepatic steatosis but elevates plasma triglycerides in mice and humans: a bedside to bench investigation","volume":"26","author":"Kim","year":"2017","journal-title":"Cell Metab"},{"key":"10.1053\/j.gastro.2020.01.051_bib151","doi-asserted-by":"crossref","first-page":"6409","DOI":"10.1073\/pnas.0401627101","article-title":"Stearoyl-CoA desaturase 1 deficiency increases fatty acid oxidation by activating AMP-activated protein kinase in liver","volume":"101","author":"Dobrzyn","year":"2004","journal-title":"Proc Natl Acad Sci U S A"},{"key":"10.1053\/j.gastro.2020.01.051_bib152","doi-asserted-by":"crossref","first-page":"2085","DOI":"10.1016\/j.cgh.2014.04.038","article-title":"The fatty acid-bile acid conjugate Aramchol reduces liver fat content in patients with nonalcoholic fatty liver disease","volume":"12","author":"Safadi","year":"2014","journal-title":"Clin Gastroenterol Hepatol"},{"key":"10.1053\/j.gastro.2020.01.051_bib153","first-page":"1448A","article-title":"One-year results of the global phase 2b randomized placebo-controlled arrest trial of aramchol, a stearoyl CoA desaturase inhibitor, in patients with NASH [abstract]","volume":"68","author":"Ratziu","year":"2018","journal-title":"Hepatology"},{"issue":"Suppl 1","key":"10.1053\/j.gastro.2020.01.051_bib154","first-page":"S11","article-title":"Has natural selection in human populations produced two types of metabolic syndrome (with and without fatty liver)?","volume":"22","author":"Caldwell","year":"2007","journal-title":"J\u00a0Gastroenterol Hepatol"},{"key":"10.1053\/j.gastro.2020.01.051_bib155","doi-asserted-by":"crossref","first-page":"165","DOI":"10.1016\/j.plipres.2012.10.004","article-title":"Molecular mechanisms and the role of saturated fatty acids in the progression of non-alcoholic fatty liver disease","volume":"52","author":"Leamy","year":"2013","journal-title":"Prog Lipid Res"},{"key":"10.1053\/j.gastro.2020.01.051_bib156","doi-asserted-by":"crossref","first-page":"863","DOI":"10.1016\/j.cmet.2016.10.012","article-title":"Physiological suppression of lipotoxic liver damage by complementary actions of HDAC3 and SCAP\/SREBP","volume":"24","author":"Papazyan","year":"2016","journal-title":"Cell Metab"},{"key":"10.1053\/j.gastro.2020.01.051_bib157","doi-asserted-by":"crossref","first-page":"1366","DOI":"10.1002\/hep.21655","article-title":"Inhibiting triglyceride synthesis improves hepatic steatosis but exacerbates liver damage and fibrosis in obese mice with nonalcoholic steatohepatitis","volume":"45","author":"Yamaguchi","year":"2007","journal-title":"Hepatology"},{"key":"10.1053\/j.gastro.2020.01.051_bib158","doi-asserted-by":"crossref","first-page":"22678","DOI":"10.1074\/jbc.M704213200","article-title":"Suppression of diacylglycerol acyltransferase-2 (DGAT2), but not DGAT1, with antisense oligonucleotides reverses diet-induced hepatic steatosis and insulin resistance","volume":"282","author":"Choi","year":"2007","journal-title":"J\u00a0Biol Chem"},{"key":"10.1053\/j.gastro.2020.01.051_bib159","doi-asserted-by":"crossref","first-page":"1972","DOI":"10.1002\/hep.30765","article-title":"Hepatocyte deletion of triglyceride-synthesis enzyme acyl CoA: diacylglycerol acyltransferase 2 reduces steatosis without increasing inflammation or fibrosis in mice","volume":"70","author":"Gluchowski","year":"2019","journal-title":"Hepatology"},{"key":"10.1053\/j.gastro.2020.01.051_bib160","doi-asserted-by":"crossref","first-page":"59","DOI":"10.1016\/j.freeradbiomed.2011.10.003","article-title":"Role of oxidative stress in the pathogenesis of nonalcoholic steatohepatitis","volume":"52","author":"Rolo","year":"2012","journal-title":"Free Radic Biol Med"},{"key":"10.1053\/j.gastro.2020.01.051_bib161","doi-asserted-by":"crossref","first-page":"519","DOI":"10.1089\/ars.2016.6776","article-title":"Oxidative stress as a critical factor in nonalcoholic fatty liver disease pathogenesis","volume":"26","author":"Spahis","year":"2017","journal-title":"Antioxid Redox Signal"},{"key":"10.1053\/j.gastro.2020.01.051_bib162","doi-asserted-by":"crossref","first-page":"9547613","DOI":"10.1155\/2018\/9547613","article-title":"Role of oxidative stress in pathophysiology of nonalcoholic fatty liver disease","volume":"2018","author":"Masarone","year":"2018","journal-title":"Oxid Med Cell Longev"},{"key":"10.1053\/j.gastro.2020.01.051_bib163","doi-asserted-by":"crossref","first-page":"1183","DOI":"10.1053\/gast.2001.23256","article-title":"Nonalcoholic steatohepatitis: association of insulin resistance and mitochondrial abnormalities","volume":"120","author":"Sanyal","year":"2001","journal-title":"Gastroenterology"},{"key":"10.1053\/j.gastro.2020.01.051_bib164","doi-asserted-by":"crossref","first-page":"1659","DOI":"10.1001\/jama.2011.520","article-title":"Effect of vitamin E or metformin for treatment of nonalcoholic fatty liver disease in children and adolescents: the TONIC randomized controlled trial","volume":"305","author":"Lavine","year":"2011","journal-title":"JAMA"},{"key":"10.1053\/j.gastro.2020.01.051_bib165","doi-asserted-by":"crossref","first-page":"328","DOI":"10.1002\/hep.29367","article-title":"The diagnosis and management of nonalcoholic fatty liver disease: practice guidance from the American Association for the Study of Liver Diseases","volume":"67","author":"Chalasani","year":"2018","journal-title":"Hepatology"},{"key":"10.1053\/j.gastro.2020.01.051_bib166","doi-asserted-by":"crossref","first-page":"1388","DOI":"10.1016\/j.jhep.2015.11.004","article-title":"EASL-EASD-EASO Clinical Practice Guidelines for the management of non-alcoholic fatty liver disease","volume":"64","year":"2016","journal-title":"J\u00a0Hepatol"},{"key":"10.1053\/j.gastro.2020.01.051_bib167","doi-asserted-by":"crossref","first-page":"927","DOI":"10.1016\/j.jhep.2018.06.008","article-title":"Endoplasmic reticulum stress signalling and the pathogenesis of non-alcoholic fatty liver disease","volume":"69","author":"Lebeaupin","year":"2018","journal-title":"J\u00a0Hepatol"},{"key":"10.1053\/j.gastro.2020.01.051_bib168","doi-asserted-by":"crossref","first-page":"781","DOI":"10.1016\/S2468-1253(19)30184-0","article-title":"Norursodeoxycholic acid versus placebo in the treatment of non-alcoholic fatty liver disease: a double-blind, randomised, placebo-controlled, phase 2 dose-finding trial","volume":"4","author":"Traussnigg","year":"2019","journal-title":"Lancet Gastroenterol Hepatol"},{"key":"10.1053\/j.gastro.2020.01.051_bib169","doi-asserted-by":"crossref","first-page":"1724","DOI":"10.1016\/j.cgh.2014.01.040","article-title":"Lack of efficacy of an inhibitor of PDE4 in phase 1 and 2 trials of patients with nonalcoholic steatohepatitis","volume":"12","author":"Ratziu","year":"2014","journal-title":"Clin Gastroenterol Hepatol"},{"key":"10.1053\/j.gastro.2020.01.051_bib170","doi-asserted-by":"crossref","first-page":"577","DOI":"10.1053\/j.gastro.2014.06.043","article-title":"Roles for chemokines in liver disease","volume":"147","author":"Marra","year":"2014","journal-title":"Gastroenterology"},{"key":"10.1053\/j.gastro.2020.01.051_bib171","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0158156","article-title":"Antifibrotic effects of the dual CCR2\/CCR5 antagonist cenicriviroc in animal models of liver and kidney fibrosis","volume":"11","author":"Lefebvre","year":"2016","journal-title":"PLoS One"},{"key":"10.1053\/j.gastro.2020.01.051_bib172","doi-asserted-by":"crossref","first-page":"1754","DOI":"10.1002\/hep.29477","article-title":"A\u00a0randomized, placebo-controlled trial of cenicriviroc for treatment of nonalcoholic steatohepatitis with fibrosis","volume":"67","author":"Friedman","year":"2018","journal-title":"Hepatology"},{"key":"10.1053\/j.gastro.2020.01.051_bib173","doi-asserted-by":"crossref","first-page":"549","DOI":"10.1002\/hep.29514","article-title":"The ASK1 inhibitor selonsertib in patients with nonalcoholic steatohepatitis: a randomized, phase 2 trial","volume":"67","author":"Loomba","year":"2018","journal-title":"Hepatology"},{"key":"10.1053\/j.gastro.2020.01.051_bib174","doi-asserted-by":"crossref","first-page":"179","DOI":"10.1038\/nature10809","article-title":"Inflammasome-mediated dysbiosis regulates progression of NAFLD and obesity","volume":"482","author":"Henao-Mejia","year":"2012","journal-title":"Nature"},{"key":"10.1053\/j.gastro.2020.01.051_bib175","doi-asserted-by":"crossref","first-page":"133","DOI":"10.1002\/hep.24341","article-title":"Fatty acid and endotoxin activate inflammasomes in mouse hepatocytes that release danger signals to stimulate immune cells","volume":"54","author":"Csak","year":"2011","journal-title":"Hepatology"},{"key":"10.1053\/j.gastro.2020.01.051_bib176","doi-asserted-by":"crossref","first-page":"162","DOI":"10.1016\/j.cell.2017.12.013","article-title":"Western diet triggers NLRP3-dependent innate immune reprogramming","volume":"172","author":"Christ","year":"2018","journal-title":"Cell"},{"key":"10.1053\/j.gastro.2020.01.051_bib177","doi-asserted-by":"crossref","first-page":"419","DOI":"10.1002\/hep.24747","article-title":"A\u00a0phase 2, randomized, double-blind, placebo-controlled study of GS-9450 in subjects with nonalcoholic steatohepatitis","volume":"55","author":"Ratziu","year":"2012","journal-title":"Hepatology"},{"key":"10.1053\/j.gastro.2020.01.051_bib178","doi-asserted-by":"crossref","first-page":"774","DOI":"10.1016\/j.cgh.2018.06.012","article-title":"Emricasan improves liver function in patients with cirrhosis and high model for end-stage liver disease scores compared with placebo","volume":"17","author":"Frenette","year":"2019","journal-title":"Clin Gastroenterol Hepatol"},{"key":"10.1053\/j.gastro.2020.01.051_bib179","doi-asserted-by":"crossref","first-page":"1643","DOI":"10.1194\/jlr.R058701","article-title":"Calcium-independent phospholipases A2 and their roles in biological processes and diseases","volume":"56","author":"Ramanadham","year":"2015","journal-title":"J\u00a0Lipid Res"},{"key":"10.1053\/j.gastro.2020.01.051_bib180","series-title":"Cellular injury in liver diseases","first-page":"105","article-title":"Hepatocyte lethal and nonlethal lipotoxic injury","author":"Hirsova","year":"2017"},{"key":"10.1053\/j.gastro.2020.01.051_bib181","doi-asserted-by":"crossref","first-page":"397","DOI":"10.1038\/nrgastro.2017.38","article-title":"Mechanisms of hepatic stellate cell activation","volume":"14","author":"Tsuchida","year":"2017","journal-title":"Nat Rev Gastroenterol Hepatol"},{"key":"10.1053\/j.gastro.2020.01.051_bib182","doi-asserted-by":"crossref","first-page":"7842","DOI":"10.1021\/bi201121m","article-title":"When galectins recognize glycans: from biochemistry to physiology and back again","volume":"50","author":"Di Lella","year":"2011","journal-title":"Biochemistry"},{"key":"10.1053\/j.gastro.2020.01.051_bib183","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0083481","article-title":"Therapy of experimental NASH and fibrosis with galectin inhibitors","volume":"8","author":"Traber","year":"2013","journal-title":"PLoS One"},{"key":"10.1053\/j.gastro.2020.01.051_bib184","doi-asserted-by":"crossref","first-page":"S100","DOI":"10.1016\/S0168-8278(18)30420-3","article-title":"A\u00a0multicenter, randomized, double-blind, PLB-controlled trial of Galectin-3 inhibitor (GR-MD-02) in patients with NASH cirrhosis and portal hypertension [abstract]","volume":"68","author":"Chalasani","year":"2018","journal-title":"J\u00a0Hepatol"},{"key":"10.1053\/j.gastro.2020.01.051_bib185","doi-asserted-by":"crossref","first-page":"e57","DOI":"10.1016\/S0618-8278(19)30103-3","article-title":"Targeted disruption of TGF-B activation by an AVB1 integrin inhibitor significantly reduces liver fibrosis in CCl4 mice and human NASH liver slices [abstract]","volume":"70","author":"Schaub","year":"2019","journal-title":"J\u00a0Hepatol"},{"key":"10.1053\/j.gastro.2020.01.051_bib186","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0175717","article-title":"A\u00a0randomised controlled trial of losartan as an anti-fibrotic agent in non-alcoholic steatohepatitis","volume":"12","author":"McPherson","year":"2017","journal-title":"PLoS One"}],"container-title":["Gastroenterology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0016508520302225?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0016508520302225?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,16]],"date-time":"2025-09-16T15:28:18Z","timestamp":1758036498000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0016508520302225"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,5]]},"references-count":186,"journal-issue":{"issue":"7","published-print":{"date-parts":[[2020,5]]}},"alternative-id":["S0016508520302225"],"URL":"https:\/\/doi.org\/10.1053\/j.gastro.2020.01.051","relation":{},"ISSN":["0016-5085"],"issn-type":[{"value":"0016-5085","type":"print"}],"subject":[],"published":{"date-parts":[[2020,5]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Therapeutic Landscape for NAFLD in 2020","name":"articletitle","label":"Article Title"},{"value":"Gastroenterology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1053\/j.gastro.2020.01.051","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2020 by the AGA Institute","name":"copyright","label":"Copyright"}]}}